

---

# Australian Type 1 Diabetes Clinical Research Network

*A Special Research Initiative* funded by the  
Australian Research Council

[www.t1dcrn.org.au](http://www.t1dcrn.org.au)

# CRN Background

- Launched by JDRF in June 2010 through a \$5M grant from the Australian Government to improve type 1 diabetes clinical activity and capacity in Australia:
  - 2 national multi-centre clinical projects
  - Australasian Diabetes Data Network development
  - 9 Pilot & Feasibility projects
  - 5 Mentored Clinical Researcher Fellowships (MCRF)
- In 2014, thanks to support from JDRF advocate families, JDRF was awarded a *Special Research Initiative* for \$35M from the Australian Research Council to further build the T1DCRN
  - 5 national multi-centre clinical projects
  - Australasian Diabetes Data Network extension
  - 1 national observational pregnancy cohort, co-funded with Helmsley Charitable Trust
  - 2 CDAs, 1 MCRF

# CRN Goal: *Positively impact the life of people with type 1 diabetes in Australia through the support and promotion of clinical research*

- *Patient-focused:*
  - Ultimate patient benefit
  - Engagement of type 1 diabetes community (research and public) is critical
- *Collaborative:*
  - A collaborative approach is applied and required
  - Research teams assembled based on the expertise and ability to solve complex issue of type 1 diabetes
- *Leveraged and connected:*
  - Partnerships benefitting from the existing international and domestic expertise and resources
  - Leverage investments
- *Information sharing:*
  - Capture valuable research information to create a long-term research legacy
  - Invest in secondary analyses of CRN outcomes and data
- *Productivity-driven:*
  - Actively support and engage in the management of clinical trials
  - Ensure research performance meets budgets and timelines

## RFA2: Innovation award:

### Targeting creative thinking, novel applications

- The T1DCRN is now focussing on addressing key challenges and complex questions to develop and advance innovation in the field.
- Calling for Letters of Intent (LOI)
  - breakthrough, cutting-edge innovation
  - falls outside current type 1 diabetes research paradigms
  - expected to make good progress towards achieving high impact on the field and eventually the lives of people with type 1 diabetes
- The proposed research must describe either the discovery or advancement of innovation along the pipeline to implementation:
  - POC
  - Basic
  - Preclinical
  - Clinical

## RFA2: Innovation award:

### Targeting creative thinking, novel applications

---

- Innovation is defined by:
  - the generation of a novel idea;
  - extending existing knowledge into a new and distinct area or application;
  - the novel use of research tools or technologies; and/or
  - the novel use of clinical tools, therapies, or strategies;

that addresses a critical barrier and/or will accelerate progress towards preventing, treating or curing the disease.

## RFA2: Innovation award:

### Targeting creative thinking, novel applications

- Support innovation in type 1 diabetes research driven by creative thinkers across Australia and is accelerated along the pathway of developing novel applications.
- Don't have to be currently working in T1D
  - BUT innovative idea has to address a T1D-specific problem!
  - T1D expertise must be included in investigator team
- If you already are working in T1D research, you must bring in expertise from outside the field
- No restrictions on number of LOI applications for PI/Co-PIs

# RFA2: Innovation award:

## Budget request

---

- \$1.5M for 2-3 years per project
- At LOI stage, budget request only indicative of size/scope
- Large, cohesive teams
- Up to 3 projects funded (based on merit and program fit)

# RFA2: Innovation award:

## Eligibility Criteria

- Aligns with goal:
  - **To positively impact the life of people with type 1 diabetes in Australia through the support and promotion of clinical research**
  - Accepting that frontier, discovery research may take years to reach the clinic or market
- Aligns with RFA Objectives
  - Collaborative across multiple research organisations and/or with industry
  - Inclusion of early-mid career and established researchers in the leadership group
  - Inclusion of at least one experienced researcher who works outside of the field of type 1 diabetes
- Formatting requirements



## RFA2: Innovation award:

### Exclusion Criteria: Duplication

---

If at any time during the assessment process JDRF or the review panel deems the scientific objectives of a proposal to:

- duplicate; or
- overlap significantly with; or
- be an extension of

the scientific objectives of a current or planned Project (in Australia and/or overseas) the proposal will be excluded from further consideration.

## RFA2: Innovation award:


### Exclusion Criteria: What we don't want to fund

- small/incremental step in an established research program
- lack a clearly articulated vision of steps to progress the innovation eventually to the end-user
- exploratory blue-sky research purely for the acquisition of data
- fails to bring external expertise into the field to drive innovation
- will have limited impact on the field or only incremental improvements in health
- harmful or high-risk; would be unlikely to be viable approaches to treating, preventing or curing type 1 diabetes due to the harm-benefit ratio

# RFA2: Innovation Award: Selection Criteria

- **Type 1 Diabetes Research Program – Innovation (40%)**
  - Extent to which the application is innovative and original, supported by convincing argument with appropriate citations
  - Likelihood of innovation progressing to end-user (beyond the life of this grant) if the project is successful
- **Type 1 Diabetes Research Program – Significance (30%)**
  - If successful, will make a significant contribution to type 1 diabetes research
- **Research Team and Environment (20%)**
  - Collaborative, cross-disciplinary, qualified, well-resourced
- **Provision of external support (10%)**
  - E.g. additional sources of funding; in-kind contributions

# RFA2: Innovation award: Process




## RFA2: Innovation award: Key Dates

LOI Application Opens	April	15	2016	
<b>LOI Application Deadline</b>	<b>July</b>	<b>22</b>	<b>2016</b>	<b>17:00 AEST</b>
Invitation to Full Submission	August	31	2016	
<b>Full Submission Deadline*</b>	<b>October</b>	<b>26</b>	<b>2016</b>	<b>17:00 AEDT</b>
Notification to Applicants	January		2017	

\*Applicants must note that the Research Office of each Administering Organisation is required to certify to JDRF all “full submission” applications in RMS360 and may have an internal closing time which precedes this deadline.

# RMS360: [RMS360 User Guide](#)



## RMS360

Username

Password

Forgot your [username?](#)

Forgot your [password?](#)

Login


## New to the System?

**Note to Institutional Officials:** please do not register on this page. A researcher or system administrator must add you to the system.

REGISTER



Australian Type 1 Diabetes  
Clinical Research Network



Welcome: Julia Warning-Researcher

Panel Invitations - (0) | Closed Panels | Home | My Profile | My Expertise | Logout

[\[Click here to hide/show instructions\]](#)

Welcome to RMS360, JDRF International's online grants management system! If you are new to RMS360, please start by clicking on **My Profile** in the upper right corner and updating your contact information. You will also need to click on **My Expertise** to associate expertise with your profile.

Please choose a tab below to do the following:

• begin and submit a proposal • edit a pending proposal • view your awarded grant history • submit required reports for your active JDRF grant • view your submission history with JDRF

If you have any grant-specific questions as you work within RMS360, please contact the appropriate [JDRF Pre-Award or Post-Award Staff member](#). For **T1DCRN grants**, please contact the appropriate [JDRF Pre-Award or Post-Award Staff Member](#). For any **non grant-specific** inquiries or issues, please contact SmartSimple Support Services via email [support@smartsimple.com](mailto:support@smartsimple.com) or phone (866) 239-0991. Support hours are Monday through Friday between 5:00am and 9:00pm US Eastern Standard Time.



Instructions

Funding Opportunities (21) Pending Proposals (8) Assigned Reviews All Reviews Chair Reviews

CRN Program	T1DCRN Innovative Grant	<a href="#">T1DCRN_RFA_LOI_Innovation_2016.pdf</a>	LOI Deadline: 07/22/2016 Full Proposal Deadline: 10/26/2016 Funding Notification Date: January - 2017 Earliest Start Date: February - 2017	<a href="#">Apply Now</a>
CCTN Fellowship	JDRF Canadian Clinical Trial Network (CCTN) Postdoctoral Fellowship in Clinical Translation in T1D Program (2016)	<a href="#">RFA_Announcement_CCTN- Lilly_Postdoctoral_Fellowships_2016.pdf</a>	Full Proposal Deadline: 05/02/2016 Funding Notification Date: August - 2016 Earliest Start Date: September - 2016	<a href="#">Call not open</a>



## Questions?

**Dorota Pawlak, PhD**

Head of Research Development

☎ + 61 (02) 9020 6106

💻 [dpawlak@jdrf.org.au](mailto:dpawlak@jdrf.org.au)

**Julia Warning, PhD**

Scientific Manager

☎ +61 (02) 9020 6105

💻 [jwarning@jdrf.org.au](mailto:jwarning@jdrf.org.au)

***RMS360 Enquiries***

**Amy Brown**

Grants Administration Officer

☎ +61 (02) 9020 6139

💻 [abrown@jdrf.org.au](mailto:abrown@jdrf.org.au)

RMS360: [jdrf.smartsimple.us](http://jdrf.smartsimple.us)